Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa
Pinilla-Rello, A. ; Huarte-Lacunza, R. ; Magallón-Martínez, A. ; Cazorla-Poderoso, L. ; Pereira-Blanco, O. ; Pérez-Moreno, M. ; Larrodé-Leciñena, I. ; Martínez Álvarez, R. M. ; López Calleja, A. I.
Resumen: Introduction. Comparative “real life” data on the effectiveness and safety of ceftolozane/tazobactam (C/T) versus other regimens (aminoglycosides/colistin/combination), in the treatment of multi-resistant (MDR) and extremely resistant (XDR) Pseudomonas aeruginosa (PA), are needed to establish positions. Material and methods. Observational, retrospective study of patients with microbiological confirmation of MDR and XDR PA from July 2016 up to December 2018 in a tertiary hospital. Variables: age, sex, comorbidities, risk factors for multidrug resistance, variables related to infection, source of infection, microorganism and type of sample, antibiotic treatment, clinical cure, microbiological cure, recurrence, mortality on admission and 30 days post-discharge. Patients were classified according to received antibiotic treatment, C/T or aminoglycosides/colistin/combination Results. A total of 405 patients with PA MDR and XDR infection (73.1% men, mean age 63 ± 15 years) were studied. An 87.1% of PA XDR and a 12.9% MDR were observed. All patients received C/T as targeted therapy and in the amino-glycosides/colistin/combination group were 73.5%. Patients in the C/T group present worse prognostic factors: septic shock (30.0%) and catheterization (90.0%) (p<0.05). There were not statistically significant differences in microbiological cure (p=0.412), recurrence (p=0.880) and clinical cure (p=0.566). There were not statistically significant differences in mortality at admission (p=0.352) or at 30 days after discharge (p=0.231). A 17.2% of the patients with aminoglycosides/colistin/combination had acute kidney injury according to RIFLE criteria and 4.3% with C/T. Conclusions. The data obtained suggest that there have been no differences in effectiveness (clinical or microbiological cure) in favour of C/T, although, in the period studied, it was used in most cases in multitreated patients with a worse prognosis. Randomized and prospective studies would be needed to establish an adequate positioning. © The Author 2021.
Idioma: Español
DOI: 10.37201/req/006.2021
Año: 2021
Publicado en: Revista española de quimioterapia 34, 5 (2021), 441-449
ISSN: 0214-3429
Factor impacto JCR: 2.515 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 206 / 279 = 0.738 (2021) - Q3 - T3
Categ. JCR: MICROBIOLOGY rank: 116 / 138 = 0.841 (2021) - Q4 - T3
Factor impacto CITESCORE: 2.3 - Pharmacology, Toxicology and Pharmaceutics (Q3) - Medicine (Q3)
Factor impacto SCIMAGO: 0.44 - Microbiology (medical) (Q3) - Medicine (miscellaneous) (Q3)
Tipo y forma: Article (Published version)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2023-05-18-15:23:33)
Visitas y descargas
Idioma: Español
DOI: 10.37201/req/006.2021
Año: 2021
Publicado en: Revista española de quimioterapia 34, 5 (2021), 441-449
ISSN: 0214-3429
Factor impacto JCR: 2.515 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 206 / 279 = 0.738 (2021) - Q3 - T3
Categ. JCR: MICROBIOLOGY rank: 116 / 138 = 0.841 (2021) - Q4 - T3
Factor impacto CITESCORE: 2.3 - Pharmacology, Toxicology and Pharmaceutics (Q3) - Medicine (Q3)
Factor impacto SCIMAGO: 0.44 - Microbiology (medical) (Q3) - Medicine (miscellaneous) (Q3)
Tipo y forma: Article (Published version)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2023-05-18-15:23:33)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2022-02-15, last modified 2023-05-19